Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Puchner, A; Gröchenig, HP; Sautner, J; Helmy-Bader, Y; Juch, H; Reinisch, S; Högenauer, C; Koch, R; Hermann, J; Studnicka-Benke, A; Weger, W; Puchner, R; Dejaco, C.
Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.
Wien Klin Wochenschr. 2019; 131(1-2): 29-44.
Doi: 10.1007/s00508-019-1448-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Hermann Josef
-
Hoegenauer Christoph
-
Juch Herbert
-
Weger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
An increasing and early-onset use of immunosuppressives and biologics has become more frequently seen among patients with inflammatory bowel diseases (IBD) and rheumatic disorders. Many women in their childbearing years currently receive such medications, and some of them in an interdisciplinary setting. Many questions arise in women already pregnant or wishing to conceive with respect to continuing or discontinuing treatment, the risks borne by the newborns and their mothers and long-term safety. Together with the Austrian Society of Rheumatology and Rehabilitation, the IBD working group of the Austrian Society of Gastroenterology and Hepatology has elaborated consensus statements on the use of immunosuppressives and biologics in pregnancy and lactation. This is the first Austrian interdisciplinary consensus on this topic. It is intended to serve as a basis and support for providing advice to our patients and their treating physicians.
- Find related publications in this database (Keywords)
-
Autoimmune disease
-
Childbearing
-
Breastfeeding
-
Prescribing
-
TNF- inhibitors
-
DMARDs